$NEO

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

NeoGenomics' RaDaR ST assay received expanded Medicare coverage for immunotherapy monitoring in late-stage solid tumors, adding to its existing indications. The assay helps track treatment response and distinguish true progress from inflammation. According to the company, it detects circulating tumor DNA at low levels, supporting recurrence risk assessment and treatment monitoring.

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

NeoGenomics (NEO) stock rose 22.3% in the past month, hitting a 52-week high of $17.08. The company beat earnings estimates in the last four quarters. For the current fiscal year, it expects $0.18 EPS on $802.67M revenue, with a 50% EPS growth. NEO has a Zacks Rank of #2 (Buy) and a VGM Score of B. Halozyme Therapeutics (HALO) is also highlighted as a strong performer in the industry.

NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Developm

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

BlackRock, Inc. filed an amended beneficial ownership report for NeoGenomics, Inc. common stock. BlackRock reported holding 20,358,331 shares, or 15.6% of the outstanding class. The filing says 19,688,877 shares have sole voting power and 20,358,331 shares have sole dispositive power, and notes iShares Core S&P Small-Cap ETF holds more than 5%.

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

Morgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).